Treatment of Pulmonary Hemangiomatosis with Recombinant Interferon Alfa-2a

Carl W. White, Henry M. Sondheimer, Edmond C. Crouch, Harry Wilson, Leland L. Fan

Research output: Contribution to journalArticlepeer-review

380 Scopus citations


PULMONARY hemangiomatosis is a rare, fatal disorder characterized by diffuse microvascular proliferation within the lung. The disease most often affects children and young adults and usually progresses rapidly, causing death from pulmonary hypertension or bleeding. Most cases have been diagnosed at autopsy. Corticosteroids and cyclophosphamide have been used for this condition, but no successful therapy has been described. We describe a patient with pulmonary hemangiomatosis who presented with digital clubbing and bilateral interstitial pulmonary disease. After a decline in the patient's exercise tolerance, therapy with interferon alfa-2a was initiated and has been continued for 14 months at the time of…

Original languageEnglish
Pages (from-to)1197-1200
Number of pages4
JournalNew England Journal of Medicine
Issue number18
StatePublished - May 4 1989


Dive into the research topics of 'Treatment of Pulmonary Hemangiomatosis with Recombinant Interferon Alfa-2a'. Together they form a unique fingerprint.

Cite this